Optometry

Patients who have undergone cataract surgery with the +3-D add version of the apodized diffractive aspheric multifocal IOL implanted bilaterally demonstrate a significant postoperative improvement in perceived driving ability.

Providing appropriate amount of care to each patient is important.

A dexamethasone intravitreal implant is a notable new therapeutic option for eyes with macular edema secondary to branch retinal vein occlusion or central retinal vein occlusion and may reduce the risk of vision loss as well as improve both the speed and incidence of visual improvement, according to one expert.

A new combined vitrectomy and phacoemulsification system was created to provide advanced technology for vitreoretinal and cataract procedures in a single, compact platform.

Analyses of data collected through 24 months of follow-up in a phase II, prospective, multicenter clinical trial support the conclusion that vascular endothelial growth factor blockade with ranibizumab is beneficial for the treatment of diabetic macular edema.

Primary readout results from 24 months of follow-up in the pivotal phase III fluocinolone acetonide in diabetic macular edema studies demonstrate that a novel investigational corticosteroid-releasing intravitreal insert provides rapid and sustained improvement in visual acuity and macular swelling with an acceptable safety profile.

Despite having a variety of imaging and treatment technologies available for retinal disease management, each technology has inherent properties that define its limitations. Integration of combinations of these technologies promises to be the best remedy for these individual shortcomings and may help achieve optimal outcomes.

Phase II study data indicate that pegaptanib sodium injection is an effective and safe treatment for diabetic macular edema.

Epimacular brachytherapy seems to be a safe and effective approach for treating neovascular age-related macular degeneration based on the 36-month results of the NVI-III pilot study, according to one expert.

ISTA Pharmaceuticals announced Oct. 16 that it had received FDA approval to market bromfenac ophthalmic solution 0.09% as a once-daily treatment for inflammation and reduction of ocular pain in patients who had undergone cataract surgery.

Port-based flow limiting is safer for the patient during vitreoretinal surgery because it is so instantaneous, does not occur at the console, and helps prevent retinal breaks.

Results of a recent clinical sutdy provide promising evidence of the value of ultra-widefield fundus autofluorescence imaging in the evaluation of age-related macular degeneration.

Results from 12 weeks of follow-up in a phase I dose-escalating, safety and tolerability study evaluating intravitreal volociximab in combination with ranibizumab for the treatment of neovascular age-related macular degeneration are favorable in showing no dose-limiting toxicity so far, according to one expert.

The idea to use a nanosecond laser-based treatment to impede the progress of age-related macular degeneration seems to have been fruitful.

Automated structural technologies can detect changes in the optic nerve head and the retinal nerve fiber layer associated with glaucoma before perimetric testing.

Endoscopic cyclophotocoagulation combined with pars plana vitrectomy is a safe and highly effective technique for treating elevated IOP in pseudophakic eyes.

A published study of treatment-na?ve patients with glaucoma prescribed a prostaglandin analogue agent re-affirms that persistence with ocular hypertension therapy is an important problem.

Results of a retrospective study analyzing images acquired by spectral-domain optical coherence tomography show that when compared with healthy control eyes, the subfoveal choroid is thinner in eyes with glaucoma and thicker in eyes with ocular hypertension.

Learn from Benjamin Franklin's wisdom how all lenses are "specialty" lenses in a sense.

Results of a retrospective chart review study show that non-penetrating Schlemm's canaloplasty can be as effective as trabeculectomy with mitomycin-C for providing IOP control in eyes with open-angle glaucoma but may be a potentially safer option because it avoids a bleb.

The experience of having a patient with early glaucoma is not uncommon.

The implantation of multiple trabecular micro-bypass implants in Schlemm's canal following phacoemulsification successfully and significantly reduced IOP for 12 months after implantation as well as the number of medications required to maintain the target IOP.

Simplification of the therapeutic regimen to enable compliance is the primary rationale for using a fixed-combination product in the management of glaucoma, but IOP-lowering efficacy along with safety and tolerability cannot be overlooked.

A portfolio of diagnostic, therapeutic, and data management tools for glaucoma can improve clinical assessment and progression analysis.

The newly expanded $132 million Kellogg Eye Center at the University of Michigan, Ann Arbor, boasts 230,000 square feet of clinical and research space across eight floors that house clinics, six operating rooms, research space, and faculty offices.

Sunwear protects eye health, enhances vision in bright sunlight, and contributes to the bottom line.

Alpha adrenoceptor agonist therapy using brimonidine tartrate 0.1% with a preservative has a wide spectrum of uses in the management of ocular hypertension and glaucoma.

Remembering the rules of the road can help clinic managers and administrators who want to keep their practice on the road with minimal breakdowns.

Selective laser trabeculoplasty is a safe and effective first-line procedure for glaucoma that works as well as the strongest anti-glaucoma medication.

A potential advance in the fight against blindness is the development of an experimental oral synthetic retinoid compound to treat two subtypes of Leber's congenital amaurosis.